Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5232 - Combination of solid and liquid biopsy genomic profiling for tumor heterogeneity characterization

Date

11 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Cancer Diagnostics;  Translational Research

Presenters

Jesus Garcia Foncillas

Citation

Annals of Oncology (2017) 28 (suppl_5): v449-v452. 10.1093/annonc/mdx378

Authors

J. Garcia Foncillas1, L. Álvarez2, A. Rodrigo2, A. Terrádez2

Author affiliations

  • 1 Cancer Institute, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 2 Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain, Madrid/ES
More

Resources

Abstract 5232

Background

Characterization of inter- and intra-tumoral heterogeneity has become a central issue in the implantation of personalized medicine. In this sense, although, the liquid biopsy has been recognized as a promising tool for prognostic, molecular profiling and monitoring of cancer disease, we are still at the beginning of its incorporation alone into the routine oncology practice. In the present study, we evaluate the usefulness of an integrated approach that combines the analysis of both solid (FFPE block) and liquid (blood sample) biopsy, into the clinical routine.

Methods

We analyzed 163 samples of metastatic patients, with different cancers types, using the OncoSTRAT&GO® solution (Biosequence SL, Valencia, Spain through OncoDNA SA, Gosselies, Belgium); that allows i) sequencing of more than 200 genes, identification of 350 genes fusion and evaluation of the expression level of tens of proteins in solid biopsy and ii) sequencing of hotspot mutations of a 27-gene panel in liquid biopsy.

Results

We focus the analysis on those actionable variants that could be detected in both solid and liquid biopsies. A complete concordance of 62.6% was observed between both types of biopsies variants. The minimum variant allele frequencies (VAFs) was found to be 0.1% and 1% in liquid and solid biopsy, respectively. The concordant and discordant VAFs were compare showing similar distributions, no significant statistical differences were found: mean values of 14.5/8.9% (P = 0.79; Mann-Whitney test) and 39.4/29.9% (P= .08; Mann-Whitney test) in liquid and solid biopsy, respectively.

Conclusions

Our findings indicate that the combination of solid and liquid biopsies analysis in clinical practice provides additional information in 37.4% of the cases. Discordant variants cannot be put down to the sensibility of the analysis and consequently should be associated to tumor heterogeneity, low tumor burden and/or treatment response. Our results show the usefulness of an integrated approach, resulting in a broad characterization of the tumor for a better disease management.

Clinical trial identification

Legal entity responsible for the study

Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.